A share price of Climb Bio Inc [CLYM] is currently trading at $4.7, down -6.56%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CLYM shares have gain 32.77% over the last week, with a monthly amount glided 125.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on October 13, 2025, and set its price target to $9. On August 15, 2025, Robert W. Baird initiated with an Outperform rating and assigned a price target of $9 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $10 on June 06, 2025. BTIG Research initiated its recommendation with a Buy and recommended $7 as its price target on May 22, 2025. Leerink Partners started tracking with an Outperform rating for this stock on December 02, 2024, and assigned it a price target of $10.
Climb Bio Inc experienced fluctuations in its stock price throughout the past year between $1.05 and $5.19. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Climb Bio Inc [NASDAQ: CLYM] shares were valued at $4.7 at the most recent close of the market. An investor can expect a potential return of 134.04% based on the average CLYM price forecast.
Analyzing the CLYM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.26 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Climb Bio Inc [NASDAQ:CLYM] is 18.38. In addition, the Quick Ratio stands at 18.38 and the Cash Ratio stands at 5.21.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Jan 05 ’26 when 7111.0 shares were purchased. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Dec 11 ’25 to buy 0.21 million shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 0.1 million shares on Dec 12 ’25.
